Frontlight ResearchEarly access
WithdrawnPhase 2
The Evaluation of the Effectiveness, Safety and Tolerability of Treatment, Using a PSMA-Lu177, in Patients with ACC- an Open, Non-commercial Clinical Trial
Key facts
- Who runs it
- Maria Sklodowska-Curie National Research Institute of Oncology
- Where
- Poland1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Withdrawn
- Phase
- Phase 2
- Started
- Jan 2024
- Expected to end
- Nov 2027
- Type of study
- Interventional
- Treatments tested
- Lutetium (177Lu) vipivotide tetraxetan
- Record updated
- 10 February 2025
- Why it stopped
- Administrative reasons
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (17)Hide the full registry criteria
Who can take part
- Signing the informed consent form to participate in the study
- Patients with inoperable, locoregionally advanced or metastatic, histopathologically confirmed adenoid cystic carcinoma of salivary gland
- Age over 18 years
- WHO performance status 0 to 2
- PSMA expression confirmed by PET/CT using 68Ga-PSMA
- Presence of measurable disease according to RECIST 1.1 criteria
- Adequate function of: bone marrow, liver, kidneys:; bone marrow: neutrophils >1500x10\^9/L; thrombocytes >150,000x10\^9/L, hemoglobin >9 g/dl liver: bilirubin <2xULN; aminotransferases <3xULN (in patients with liver metastases <5xULN) kidney: eGFR >50 ml/min albumin >2.5 mg/ml
- For women of reproductive age: confirmed negative pregnancy test
- The need to use of a highly effective method of contraception
Who cannot take part
- Concomitant treatment of another cancer
- Previous treatment with 177Lutetium-labeled PSMA
- Patients with metastases to the brain, meninges or heart
- Severe or significant additional diseases in the opinion of the investigator
- Lack of effective contraception during childbearing age
- Pregnancy or breastfeeding
- Urinary tract obstruction and/or hydronephrosis
- Myelosuppressive or nuclear treatment later than 4 weeks after qualification
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Non-commercial phase 2 clinical trial to evaluate the effectiveness, safety and tolerability of treatment using prostate-specific membrane antigen (PSMA) labeled with 177Lutetium in patients with recurrence and/or metastases in adenoid cystic carcinoma originating from the salivary glands of the head and neck region.
Read full original descriptionShow less
Patients with PSMA receptor expression confirmed by PET/CT after administration of 68Ga-PSMA I\&T will be eligible for treatment.
The group in the trial
- ExperimentalTreatment being tested
Treatment will consist of administration of 6 cycles of lutetium (177Lu) vipivotide-tetraxetan with an activity of 200 mCi (7.4 GBq) at intervals of 6 weeks.
Treatment: Lutetium (177Lu) vipivotide tetraxetan
Data and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- The Evaluation of the Effectiveness, Safety and Tolerability of Treatment, Using a Specialized Prostate-specific Membrane Antigen (PSMA) Labeled with Lutetium177, in Patients with Recurrent And/or Metastatic Adenoid Cystic Carcinoma Originating from the Salivary Glands - an Open, Non-commercial Clinical Trial
- Record updated
- 10 February 2025